Continuous Disclosure Policy
As a listed entity, ACL will need to comply with the continuous disclosure requirements of the ASX Listing Rules and the Corporations Act. Subject to the exceptions contained in the ASX Listing Rules, ACL will be required to immediately disclose to ASX any information concerning the Company which is not generally available and which a reasonable person would expect to have a material effect on the price or value of ACL’s Shares were that information to be generally available.
ACL is committed to observing its continuous disclosure obligations. As such, this policy sets out certain procedures and measures which are designed to ensure that the Company complies with its continuous disclosure obligations and provides timely disclosure in accordance with those obligations. Information will be communicated to Shareholders through the lodgement of all relevant financial and other information with ASX, and continuous disclosure announcements will be made available on the Company website at www.clinicallabs.com.au
Shareholder Communication Policy
The Board’s aim is to ensure that Shareholders are informed in a timely and readily accessible manner of all major developments affecting the state of affairs of ACL. Information will be communicated to Shareholders through the lodgement of information with ASX as required by ACL’s continuous disclosure obligations and publishing information on ACL’s website at www.clinicallabs.com.au. The website will contain information about ACL, including periodic releases, key policies, the terms of reference of Board committees and other information relevant to Shareholders. All announcements made to the market and any other relevant information will be posted on the website following release to ASX.